Noema Pharma

Noema Pharma is a clinical-stage biotech company advancing a late-stage portfolio of oral small molecule therapeutics with well-characterized mechanisms for people living with neurological and related disorders. Founded in 2019 with a seed investment from Sofinnova Partners and four clinical-stage assets in-licensed from Roche, the company pursues both orphan and larger CNS indications — including vasomotor symptoms, Tourette syndrome, and other debilitating neurological conditions — for which there are significant unmet medical needs and compelling scientific rationales for superior clinical benefit.